Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347
Hangzhou Tigermed Consulting Co., Ltd. Class A — H1 2024 Earnings Presentation
32 slides from Hangzhou Tigermed Consulting Co., Ltd. Class A's earnings presentation, August 2024
Slide 1: 2024 Interim Results
2024 Interim Results Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK August 2024
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (
Slide 3: Interim Results Overview
(Doermed O1 Interim Results Overview YEARS ANNIVERSARY
Slide 4: Clear QoQ Improvement Seen from Q2 2024 Performance
Clear QoQ Improvement Seen from Q2 2024 Performance Net profit attributable to shareholders of the Company after deducting Revenue Gross Profit and Margin extraordinary gain or loss(1) (RMB mm) (RMB mm) (RMB mm) 37.8% 41.5% 18.3% 19.9% +2.3% +12.2% +11.3% 1,660.2 1,698.0 704.9 628.1 337.2 303.1 1Q20
Slide 5: 1H2024 Key Financials
1H2024 Key Financials Net profit attributable to shareholders of the Company after deducting Revenue Gross Profit and Margin extraordinary gain or loss(1) (RMB mm) (RMB mm) (RMB mm) 39.9% 39.7% 21.4% 19.1% -9.5% -10.0% -19.3% 3,710.9 3,358.2 1,481.1 1,607.5 1,333.0 793.5 1,721.1 645.3 640.3 705.0 2,
Slide 6: Revenue Breakdown by China and Overseas Markets
Revenue Breakdown by China and Overseas Markets China Revenue Overseas Revenue Revenue Breakdown by Region (RMB mm) (RMB mm) -10.4% -8.4% 56% 1H2023 44% 2,087.4 China Overseas 1,870.4 1,623.5 1,487.8 1H2024 44% 56% 1H2023 1H2024 1H2023 1H2024 China Overseas 6
Slide 7: Cost of Services
Cost of Services Cost of Services Breakdown by Nature and as % of Revenue (RMB mm) 60.1% 60.3% 2,229.8 -9.2% 2,025.2 6.3% 7.3% 23.6% 19.0% 30.2% 34.0% 1H2023 1H2024 Direct labor costs Direct project-related costs Overhead costs 7
Slide 8: Operating Expenses
Operating Expenses Selling and Marketing Expenses Administrative Expenses and R&D Expenses and as % Share-based Compensation and as % of Revenue as % of Revenue of Revenue and as % of Revenue (RMB mm) (RMB mm) (RMB mm) (RMB mm) 2.4% 3.0% 9.3% 11.2% 3.5% 3.7% 1.5% 1.4% +13.9% +8.7% -2.7% -13.4% 101.4
Slide 9: Business Updates: Clinical Trial Solutions (CTS)
02 Business Updates Clinical Trial Solutions (“CTS”)
Slide 10: Clinical Trial Solutions (CTS)
Clinical Trial Solutions (“CTS”) Segment Revenue Segment Gross Profit and Margin (RMB mm) (RMB mm) 39.7% 38.4% -22.2% -24.9% 2,103.4 1,637.1 835.8 628.0 1H2023 1H2024 1H2023 1H2024 10
Slide 11: CTS Key Business Updates
CTS Key Business Updates Number of Ongoing Drug Clinical Number of Ongoing Drug Clinical Research Projects by Phase(1) Research Projects by Region(1) 800 800 772 772 752 752 91 55 74 62 84 59 35 30 31 208 207 194 185 192 171 146 136 147 503 537 499 332 330 340 06/30/2023 12/31/2023 06/30/2024 06/30/
Slide 12: Overseas Clinical Operation Business Updates
Overseas Clinical Operation Business Updates Number of Ongoing Overseas Drug Clinical Research(1) Total employees reached 9,348, covering 37 countries including 1,722 employees based overseas 269 263 Completed the acquisition of the Japanese CRO Medical Edge, 253 further strengthening our DMSA servi
Slide 13: Focus Strategies to Drive Long-term Growth in 1H2024
Focus Strategies to Drive Long-term Growth in 1H2024 Established three business units by therapeutic areas including Cell and Gene Therapy (CGT), GLP1 Receptors, and Radiopharmaceuticals, integrating resources and business experience to provide customized R&D strategies and clinical development serv
Slide 14: Dynamic Industry Trend Observed in China 1H2024
Dynamic Industry Trend Observed in China 1H2024 Stable Industry Development Strong Policy Support (5) • The Chinese clinical outsourcing service market is expected to maintain a CAGR • In July 2024, the State Council executive meeting (国务院常务会议) approved the of 11% over the next five years (2024-2028
Slide 15: Overseas Clinical Operation Business Updates (Cont'd)
Overseas Clinical Operation Business Updates (Cont’d) North America ⚫ Clinical operation business and new orders in North America continued to grow rapidly, with local medical monitoring (MM) and pharmacovigilance (PV) teams established in North America ⚫ As of June 30, 2024, the size of our U.S. cl
Slide 16: CTS Key Business Updates
CTS Key Business Updates Regulatory Affairs (“RA”) ⚫ As of June 30, 2024, we had a total of 1,121 accumulated RA project experience ⚫ Added 21 new U.S. Food and Drug Administration IND (“FDA IND”) projects, of which 19 of them have successfully filed ⚫ Assisted 2 products to be registered and approv
Slide 17: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Pharmacovigilance (“PV”） ⚫ The global pharmacovigilance team has more than 150 employees, established a local PV team in the U.S for the first time ⚫ As of June 30, 2024, we have more than 250 customers globally, accumulated 900+ project experiences, and served 36 a
Slide 18: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Decentralized Clinical Trials （”DCT”s） ⚫ Assisted an American MNC pharmaceutical company in obtaining approval in China for a new generation of CGRP receptor antagonists for the treatment of migraines; became a preferred supplier for a European MNC pharmaceutical co
Slide 19: Business Updates: Clinical-related and Lab Services (CRLS)
03 Business Updates Clinical-related and Lab Services (“CRLS”)
Slide 20: Clinical-related and Lab Services (CRLS)
Clinical-related and Lab Services (“CRLS”) Segment Revenue Gross Profit and Margin (RMB mm) (RMB mm) 40.1% 41.0% +7.1% +9.3% 1,721.1 1,607.5 705.0 645.3 1H2023 1H2024 1H2023 1H2024 20
Slide 21: CRLS Key Business Updates
CRLS Key Business Updates Project Status for Key CRLS Services Data Management and Statistical Analysis Site Management Laboratory Services Completed Conducted 335 by team based overseas 2,110 5,818 5,173 Completed 4,667 Conducted 489 by team Completed based 2,872 in China 306 157 273 83 203 228 202
Slide 22: CRLS Key Business Updates (Cont'd)
CRLS Key Business Updates (Cont’d) Data Management & Statistical Analysis (“DMSA”) ⚫ Assisted 11 new drugs approvals in China, U.S., and Japan in first half 2024 ⚫ Established a data science team consisting of 25 employees, mainly responsible for data-related tool development, quality solutions, new
Slide 23: CRLS Key Business Updates (Cont'd)
CRLS Key Business Updates (Cont’d) Site Management (“SMO”) ⚫ As of June 30, 2024, we completed 165 site management projects and 2,110 ongoing site management projects ⚫ In first half 2024, new orders achieved 34% YoY growth, and the proportion of international MNC and leading biotech companies conti
Slide 24: Other Updates
(Doermed O04 Other Updates YEARS ANNIVERSARY
Slide 25: Updates of Investment Activities
Updates of Investment Activities Realized Investment Gain and Fair Value Gain(1) （RMB mm） 529.8 ⚫ Portfolio included 181 companies in the healthcare industry and 61 investment funds as of June 30, 2024 ⚫ RMB 10,549.6 mm balance as of June 30, 2024 ⚫ Invested RMB 317.0 mm in unlisted equities; and RM
Slide 26: Employee Base
Employee Base The number of our employees slightly decreased to 9,348 as of June 30, 2024 from 9,701 as of Dec 31, 2023 Employees Mix by Function(1) Employees Mix by Geography(1) Management and administration Overseas and Hong Kong China, Macao China, Taiwan China 564 1,722 Marketing and 6% business
Slide 27: Appendix
(Doermed O05 Appendix YEARS ANNIVERSARY
Slide 28: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss Six months ended June 30, (RMB 000s) 2023 2024 Ⅰ. Total Revenue 3,710,850 3,358,244 Including: Operating Revenue 3,710,850 3,358,244 Interest Revenue - - Premium earned - - Fees and commission income - - Ⅱ. Cost of services (2,720,025) (2,626,270) Including:
Slide 29: Net profit attributable to shareholders after deducting extraordinary gain or loss
Net profit attributable to shareholders of the Company after deducting extraordinary gain or loss Six months ended June 30, (RMB 000s) 2023 2024 Profit attributable to owners of the Company 1,388,337 492,849 Adjusted for: Loss/(gain) from disposal of non-current assets(1) 6 (1,490) Government grants
Slide 30: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position (RMB 000s) As of December 31, 2023 As of June 30, 2024 NON-CURRENT ASSETS 18,336,601 22,770,481 Long-term equity investments 2,977,028 3,518,375 Other equity instrument investments 14,508 9,872 Other non-current financial assets 10,231,702 10,497,205 Fixe
Slide 31: Consolidated Statement of Financial Position (Cont'd)
Consolidated Statement of Financial Position (Cont’d) (RMB 000s) As of December 31, 2023 As of June 30, 2024 CURRENT LIABILITIES 4,138,736 5,332,416 Short-term borrowings 1,969,694 2,767,059 Notes payables - 3,399 Accounts payables 249,308 227,113 Contract liabilities 680,489 772,246 Employee benefi
Slide 32: 300347.SZ / 3347.HK
300347.SZ / 3347.HK Hangzhou Tigermed Consulting Co., Ltd. www.tigermedgrp.com
Hangzhou Tigermed Consulting — H1 2024 Earnings Presentation on 6ix